2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Bioinformatics, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3312 An alternating-cycle hybrid immunochemotherapy paradigm improves molecular responses and survival outcomes in Philadelphia chromosome–positive acute lymphoblastic leukemia

Liping Xie, Jinjun Yang2, Yang Dai3, Yong Guo4, Jiazhuo Liu5, Xiaoou Huang6, Yan Zeng, MD, PhD7, Chenlu Yang, PhD8, Xiao Shuai9, Jie Ji10, Chuan He Sr, ????11, Li Hou12, He LI13, Shuying Zeng14, Xiao Jian15, Ya Zhang16, Yu Wu, MD17
1 West China Hospital of Sichuan University, Chengdu, China
2 West China Hospital of Sichuan University, Chengdu, China
3 West China Hospital of Sichuan University, Chengdu, China
4 West China Hospital of Sichuan University, Chengdu, China
5 West China Hospital of Sichuan University, Chengdu, China
6 West China Hospital of Sichuan University, Chengdu, China
7 Chengdu Second People’s Hospital of Sichuan University, Chengdu, China
8 West China Hospital of Sichuan University, Chengdu, China
9 West China Hospital of Sichuan University, Chengdu, China
10 West China Hospital of Sichuan University, Chengdu, China
11 West China Hospital of Sichuan University, Chengdu, China
12 West China Hospital of Sichuan University, Chengdu, China
13 West China Hospital of Sichuan University, Chengdu, China
14 West China Longquan Hospital of Sichuan University, Chengdu, China
15 Zigong First People's Hospital, Zigong, China
16 Mianyang Central Hospital, Mianyang, China
17 West China Hospital of Sichuan University, Chengdu, China
Background

The prognosis of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) has improved substantially with tyrosine kinase inhibitors (TKIs); however, persistent molecular measurable residual disease (MRD), particularly among patients with IKZF1 alterations, remains a major determinant of relapse and survival outcomes. We investigated whether an alternating-cycle hybrid immunochemotherapy paradigm could enhance molecular responses and improve clinical outcomes in patients with Ph+ ALL.

Methods

We conducted a prospective multicenter cohort study including 79 adults with newly diagnosed Ph+ ALL across five participating centers. The study was approved by the Ethics Committee of West China Hospital of Sichuan University (approval No. 2025[912]) and prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2600126815).

All patients received induction therapy with a TKI combined with vincristine and prednisone (VP). During consolidation, treatment allocation was based on patient preference, with patients receiving either a novel alternating-cycle hybrid immunochemotherapy paradigm (Plan A) or a conventional TKI-based chemotherapy strategy (Plan B). Plan A consisted of a TKI backbone with five alternating cycles of DVP (dexamethasone, vincristine, and prednisone), attenuated-dose pulsed blinatumomab (28 μg/day for 14 days per cycle), methotrexate, a second course of blinatumomab, and cytarabine, whereas Plan B consisted of TKI-based alternating chemotherapy without blinatumomab. Serial molecular MRD monitoring was performed using BCR::ABL1 quantitative polymerase chain reaction after induction therapy. After consolidation, subsequent treatment strategies, including allogeneic hematopoietic stem cell transplantation (allo-HSCT), TKI plus blinatumomab-based maintenance, or TKI-based maintenance, were determined according to treatment response, early and persistent molecular MRD status, and patient preference. Patients who experienced relapse at any time during follow-up received salvage therapy. Molecular responses at 3, 6, and 12 months, large IKZF1 deletion/IKZF1-plus status, hematologic relapse, central nervous system leukemia (CNSL), overall survival (OS), and relapse-free survival (RFS) were evaluated.

Results

Among 79 patients, 29 received Plan A, whereas 50 received Plan B. Baseline characteristics were comparable between groups, including age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, white blood cell count, large IKZF1 deletion, IKZF1-plus status, chemotherapy backbone, and allo-HSCT status (all p > 0.05).

Plan A was associated with improved molecular responses, particularly among patients with IKZF1 abnormalities. Among patients with large IKZF1 deletion, molecular MRD negativity rates at 6 and 12 months were significantly higher in patients receiving Plan A compared with those receiving Plan B (100% vs 65.4%, p = 0.009; and 100% vs 60.9%, p = 0.007, respectively). Among patients with IKZF1-plus alterations, Plan A was associated with higher MRD negativity rates at 6 months (100% vs 53.8%, p = 0.015) and 12 months (100% vs 38.5%, p < 0.001).

Six-month molecular MRD negativity was associated with reduced hematologic relapse (11.5% vs 58.3%, p < 0.001) and superior survival outcomes, including improved RFS (HR, 11.22; 95% CI, 3.63–34.66; p < 0.001) and OS (HR, 7.89; 95% CI, 2.07–30.15; p < 0.001). Sustained molecular remission at 12 months was associated with further reduced hematologic relapse (6.8% vs 90.9%, p < 0.001) and improved RFS (HR, 24.15; 95% CI, 6.49–89.85; p < 0.001) and OS (HR, 52.68; 95% CI, 6.25–443.93; p < 0.001) outcomes.

Among patients with IKZF1-plus alterations, hematologic relapse occurred less frequently in patients receiving Plan A compared with those receiving Plan B (8.3% vs 53.3%, p = 0.003), with superior RFS and OS observed in the Plan A group (log-rank p = 0.002 and 0.035, respectively). Despite concerns regarding CNSL during blinatumomab-containing strategies, the 14-day pulsed schedule was not associated with an increased incidence of CNSL (10.3% vs 8.0%, p = 0.703).

Conclusions

The alternating-cycle hybrid immunochemotherapy paradigm was associated with deeper and more durable molecular responses and improved survival outcomes in patients with Ph+ ALL, particularly among those harboring IKZF1-plus alterations, without increasing CNSL incidence.

Jinjun Yang: No relevant conflicts of interest to declare.